Jul 15, 2026
AbbVie (ABBV) Gets $260 Price Target Upgrades Amid Growing Valuation Worries
AbbVie (ABBV) receives $260 price target upgrades from Citi and UBS, but Neutral ratings persist as Zacks flags Sell and valuation concerns emerge.
The post AbbVie (ABBV) Gets $260 Price Target Upgrades Amid Growing Valuation Worries appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
SpaceX (SPCX) Stock: Expands AI Cloud Business With $20.8 Billion in New Contrac...
- 1 hour ago
SanDisk (SNDK) Stock Rebounds in Premarket Despite Post-Earnings Volatility
- 1 hour ago
SK Hynix (000660) Stock: $3B China Facility Under Strategic Review Amid Export C...
- 1 hour ago
First Solar (FSLR) Stock Soars 8% on Trump’s Chinese Polysilicon Tariff Announce...
- 1 hour ago
Analyst Outlook on Quantum Computing: IonQ (IONQ), IBM (IBM), and Alphabet (GOOG...